VEGFA and colonic neoplasm: Evidence of VEGFA as the sole MR unique to Cubisbel potentially suggests a clinical advantage for the combination of Cubisbel with targeted anti-VEGF therapies routinely used to treat colon cancer such as bevacizumab [62].